CD8A and neoplasm: To ensure that CXCR3 expression was required for CD8+ T-cell infiltration and anti-tumor effects, Vonderhaar et al. treated CXCR3 KO mice, implanted with KPC tumors as well, with the same STING treatment regimen and found no anti-tumor effects and no difference in CD8+ T-cell infiltration compared to control, while the CCR5 receptor expression was unchanged [125].